DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Funds preclinical-to-IND-enabling work on an ALS drug that already has proof-of-concept efficacy data and a lead compound in hand.
By the time a treatment reaches this award, the easy question — does it work at all, even a little — is supposed to already be answered. This funds the expensive middle stretch: turning a validated lead into something ready for an FDA Investigational New Drug application.
The bar to enter is concrete. An application needs a lead compound already in hand, with proof-of-concept efficacy data from a…
Preclinical-to-IND-enabling therapeutic development for ALS, entering with a lead compound already in hand and proof-of-concept efficacy data from at least one preclinical model, with mechanism-specific target-engagement and pharmacodynamic biomarker development run in parallel to improve trial design, patient selection or interpretation. Candidates that already hold an IND, and biomarkers not tied to the therapeutic programme, are out of scope.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up